Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Aeglea Bio Therapeutics Inc    AGLE

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/17/2018 01/18/2018 01/19/2018 01/22/2018 01/23/2018 Date
6.49(c) 6.6(c) 6.75(c) 7.4001(c) 7.51 Last
147 678 87 251 115 555 155 687 32 565 Volume
+6.05% +1.69% +2.27% +9.63% +1.49% Change
More quotes
Financials ($)
Sales 2017 4,88 M
EBIT 2017 -29,7 M
Net income 2017 -29,3 M
Finance 2017 30,2 M
Yield 2017 -
Sales 2018 2,37 M
EBIT 2018 -37,9 M
Net income 2018 -37,4 M
Finance 2018 21,7 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 19,1x
EV / Sales2018 42,9x
Capitalization 123 M
More Financials
Company
Aeglea Biotherapeutics, Inc. operates as a biopharmaceutical company, which engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer.It develops AEB1102, an amino acid for the degradation of arginine in the circulation, as well as for the treatment... 
More about the company
Surperformance© ratings of Aeglea Bio Therapeutics In
Trading Rating : Investor Rating :
More Ratings
Latest news on AEGLEA BIO THERAPEUTICS IN
01/19 AEGLEA BIO THERAPEUTICS : BioTherapeutics to Present Preclinical Data at 2018 Ke..
01/18 Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia ..
2017 Aeglea BioTherapeutics to Present at BMO Capital Markets Prescriptions for Su..
2017 AEGLEA BIO THERAPEUTICS : BioTherapeutics Doses First Pediatric Patient with Arg..
2017 AEGLEA BIO THERAPEUTICS : BioTherapeutics Doses First Pediatric Patient with Arg..
2017 AEGLEA BIO THERAPEUTICS : reports 3Q loss
2017 AEGLEA BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, Fi..
2017 AEGLEA BIO THERAPEUTICS : BIOTHERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANAL..
2017 AEGLEA BIO THERAPEUTICS : BioTherapeutics Provides Corporate Update and Reports ..
2017 Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immuno..
More news
Sector news : Bio Therapeutic Drugs
08:48a Drug Firms Bet Billions on Biotech -- WSJ
01/22 Stocks hit record as senators reach deal to end shutdown
01/22 Big Drugmakers Pay Big Prices for Promising Biotechs
01/22 Dealmaking drives European stocks as equity melt-up continues
01/22 Biotech M&A takes off as Sanofi and Celgene spend $20 billion
More sector news : Bio Therapeutic Drugs
Latest Tweets
01/14Aeglea Bio Therapeutics $AGLE Given News Sentiment Rating of 0.04  
01/10UPSIDE MOMENTUM ALERT: $AGLE AEGLEA BIOTHERAPEUTICS ? TradeIdeas via  
01/10MOST ACTIVE ALERT: $AGLE AEGLEA BIOTHERAPEUTICS ? TradeIdeas via  
01/06Aeglea Bio Therapeutics Inc $AGLE Given Consensus Recommendation of “Strong B.. 
2017Get the latest news and updates for $ABIL $AGLE $CDNA $INCR $SR automatically.. 
More tweets
Qtime:99
News from SeekingAlpha
2017 Aeglea Biotherapeutics (AGLE) Presents At BMO Capital Markets 2017 Prescripti..
2017 YOUR DAILY PHARMA SCOOP : Gilead's Potential, Celgene CAR-T Candidate, Cellectar..
2017 Midday Gainers / Losers
2017 HEALTHCARE GAINERS / LOSERS AS OF 11 : 00 am
2017 Aeglea Biotherapeutics (AGLE) Presents At Society For Immunotherapy Of Cancer..
Chart AEGLEA BIO THERAPEUTICS IN
Duration : Period :
Aeglea Bio Therapeutics In Technical Analysis Chart | AGLE | US00773J1034 | 4-Traders
Technical analysis trends AEGLEA BIO THERAPEUTICS IN
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 12,3 $
Spread / Average Target 66%
EPS Revisions
Managers
NameTitle
Anthony G. Quinn Chief Executive Officer & Director
Armen B. Shanafelt Chairman
Charles N. York Chief Financial Officer & Vice President
Scott W. Rowlinson Vice President-Research
James Wooldridge Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
AEGLEA BIO THERAPEUTICS INC36.79%123
GILEAD SCIENCES13.04%106 315
VERTEX PHARMACEUTICALS5.41%40 948
REGENERON PHARMACEUTICALS-1.18%40 382
GENMAB13.75%11 797
BIOVERATIV INC18.90%11 230